Evaluation of Low-Level Laser Therapy Efficacy in Pain Management of Grade 2 Oral Mucositis Induc… (NCT03955224) | Clinical Trial Compass
WithdrawnPhase 2
Evaluation of Low-Level Laser Therapy Efficacy in Pain Management of Grade 2 Oral Mucositis Induced by Radiotherapy or Chemoradiotherapy: a Study in Patients With Upper Aerodigestive Tract Cancer
Stopped: Withdrawn due to lack of recruitment
France0Started 2021-03
Plain-language summary
Prospective, monocentric, randomized phase II study evaluating Low-Level Laser Therapy (LLLT) as a treatment for the pain due to grade 2 oral mucositis in patients with upper aero-digestive tract cancer treated by radiotherapy or chemoradiotherapy.
Patients with upper aero-digestive tract cancer receiving their first cervicofacial radiotherapy or chemoradiotherapy will be included in this study if they suffer from oral mucositis due to their treatment.
The study procedure will consist in 5 applications of the LLLT that will be performed at three days intervals for a maximum duration of 15 days.
Each patient will be followed until 3 days after the end of the study treatment, for a total duration of the study of 18 days.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥ 18 years.
✓. Patients with upper aero-digestive tract cancer receiving a first cervicofacial radiotherapy or chemoradiotherapy
✓. Patients with a grade 2 mucositis (according to the NCI CTCAE version 5.0) appearing during treatment.
✓. Patients available to perform the LLLT treatment: 5 visits at 3 days intervals
✓. Patients must provide written informed consent prior to any study specific procedures.
✓. Patients affiliated to a Social Health Insurance in France.
Exclusion criteria
✕. Patients who have already received a cervicofacial radiotherapy
✕. Patients who have already received an induction chemotherapy for their upper aero-digestive tract cancer
✕. Patients under targeted therapy for their upper aero-digestive tract cancer
✕
What they're measuring
1
Rate of patients who didn't need a dose increase or introduction of new analgesics for mouth pain during the study compared to baseline
✕. Patients with a non-grade 2 mucositis (according to the NCI CTCAE version 5.0)
✕. Patients with ulceration or any other oral mucosa pathology than mucositis
✕. Pregnant or breastfeeding women
✕. Any psychological, familial, geographical or sociological condition which does not allow to respect the medical follow-up and/or compliance to study procedure